Skip to main content
SpringerLink
Log in

Octocog alfa, plasma/albumin-free method: profile report

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. McCormack PL, Plosker GL. Octocog alfa, plasma/albumin-free method. Drugs 2005; 65(18): 2613–20

    Article  PubMed  CAS  Google Scholar 

  2. Franchini M. Octocog alfa, plasma/albumin-free method: a viewpoint. Drugs 2005; 65(18): 2621

    Article  Google Scholar 

  3. Ingerslev J. Octocog alfa, plasma/albumin-free method: a viewpoint. Drugs 2005; 65(18): 2621–2

    Article  Google Scholar 

  4. Baxter Healthcare Corporation. Advate (octocog alfa [recombinant coagulation factor VIII]): product monograph. 2004 Sep

  5. Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004 Sep; 10(5): 428–37

    Article  PubMed  CAS  Google Scholar 

  6. Liesner R, Shapiro A, Blanchette V, et al. Pharmacokinetics, safety and efficacy of ADVATE rAHF-PFM in previously treated patients less than 6 years old [poster]. 20th Congress of the International Society on Thrombosis and Haemostasis; 2005 Aug 6–12; Sydney

  7. Négrier C, Shapiro A, Pabinger I, et al. Clinical efficacy and safety evaluation of ADVATE antihemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM) during surgical and invasive procedures [poster]. 20th Congress of the International Society on Thrombosis and Haemostasis; 2005 Aug 6–12; Sydney

  8. Gomperts ED, Ewenstein BM, O’Banion ME, et al. The growing body of evidence on safety profile of ADVATE antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) [poster]. 2004 Annual Meeting of the American Society of Hematology; 2004 Dec 4–7; San Diego (CA)

  9. Ewenstein BM, Gomperts ED, Pearson S, et al. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study. Haemophilia 2004 Sep; 10 (5): 491-8

  10. Ananyeva N, Khrenov A, Darr F, et al. Treating haemophilia A with recombinant blood factors: a comparison. Expert Opin Pharmacother 2004 May; 5(5): 1061–70

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Octocog alfa, plasma/albumin-free method: profile report. Drugs Ther. Perspect 22, 7–8 (2006). https://doi.org/10.2165/00042310-200622060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622060-00002

Search

Navigation